Showing results (21-30 of 6,003) with videos related to

Sort By:
Pageof 601
Molecular Cancer Therapeutics|April 8, 2022
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance MechanismsTimothy T Ferng, Daisuke Terada, Makoto Ando, et al.
Molecular Cancer Therapeutics|April 13, 2022
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted TherapiesNeil A O'Brien, Holly K T Huang, Martina S J McDermott, et al.
Molecular Cancer Therapeutics|July 8, 2010
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancerHop S Tran Cao, Michael Bouvet, Sharmeela Kaushal, et al.
Molecular Cancer Therapeutics|July 1, 2010
p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-MycJi-Hak Jeong, Shin-Sung Kang, Kwan-Kyu Park, et al.
Molecular Cancer Therapeutics|July 1, 2010
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerDavid L Schwartz, James A Bankson, Robert Lemos, et al.
Molecular Cancer Therapeutics|July 1, 2010
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805Fabienne Baffert, Catherine H Régnier, Alain De Pover, et al.
Molecular Cancer Therapeutics|July 1, 2010
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell linesEdward B Garon, Richard S Finn, Wylie Hosmer, et al.
Molecular Cancer Therapeutics|October 28, 2010
SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeuticsAndrea D Basso, Ming Liu, Chaoyang Dai, et al.
Molecular Cancer Therapeutics|October 7, 2010
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancerJohn J Tentler, Sujatha Nallapareddy, Aik Choon Tan, et al.
Molecular Cancer Therapeutics|September 30, 2010
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancerDavid Luyimbazi, Argun Akcakanat, Priscilla F McAuliffe, et al.
Pageof 601